{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T11:06:23Z","timestamp":1782644783653,"version":"3.54.5"},"reference-count":29,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006084","name":"Office of AIDS Research","doi-asserted-by":"publisher","award":["HHSN269201400012C"],"award-info":[{"award-number":["HHSN269201400012C"]}],"id":[{"id":"10.13039\/100006084","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background\/Aims<\/jats:title><jats:p>In people with opioid use disorder (OUD), buprenorphine is a vital treatment to decrease opioid use and overdose. The US Food and Drug Administration's prescribing information for buprenorphine advises dosing up to 24\u2009mg\/day; however, doses of buprenorphine up to 32\u2009mg have been shown to be safe and effective. We compared outcomes associated increased dosing from 24 to 32\u2009mg\/day.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Prospective cohort investigation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>Low\u2010barrier buprenorphine clinic in Washington, District of Columbia, USA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>Participants in the ANCHOR study (people with hepatitis C virus (HCV), OUD, and active opioid misuse who were treated for HCV and offered buprenorphine) who received buprenorphine at doses of 24 and\/or 32\u2009mg\/day. 72 participants were included in the analysis: 24 (33%) patients stabilized on 24\u2009mg, and 48 (67%) patients stabilized on 32\u2009mg. Patients were predominantly male (78%), Black (96%), unstably housed (57%), and used opioids by injection (93%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Measurements<\/jats:title><jats:p>Patient\u2010reported drug use, use frequency, triggers for use, and urine drug screens were collected at each visit. For analysis, the cohort was divided into individuals stabilized on 24\u2009mg (24\u2009mg cohort) or 32\u2009mg (32\u2009mg cohort). Drug use outcomes were assessed between cohorts at 24\u2009mg dosing and at respective maximum dosing. Within the 32\u2009mg cohort, outcomes were compared at 24\u2009mg versus 32\u2009mg dosing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Findings<\/jats:title><jats:p>Within the 32\u2009mg cohort, increased dosing from 24 to 32\u2009mg was associated with a decline in opioid use (68.5% [5.2%] at 24\u2009mg vs 59.5% [5.6%] at 32\u2009mg; <jats:italic>P<\/jats:italic> = 0.02), frequency of use per week (1.58 [0.19] at 24\u2009mg vs. 1.15 [0.16] at 32\u2009mg; <jats:italic>P<\/jats:italic> = 0.0002) and physiologic triggers for use (38.2% [6.0%] at 24\u2009mg vs 7.0% [1.9%] at 32\u2009mg; <jats:italic>P<\/jats:italic> &lt; 0.0001). At the end of the study period, there were significantly more patients retained in the 32\u2009mg cohort (78.7%) compared with the 24\u2009mg cohort (50.0%, <jats:italic>P<\/jats:italic> = 0.02).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Higher buprenorphine dosing (32\u2009mg\/day) appears to improve outcomes in people with opioid use disorder, even in the absence of abstinence.<\/jats:p><\/jats:sec>","DOI":"10.1111\/add.16600","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T04:31:03Z","timestamp":1720499463000},"page":"1964-1972","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Dose\u2010specific clinical outcomes in patients with opioid use disorder treated with 24\u201332\u2009mg\/day of buprenorphine"],"prefix":"10.1111","volume":"119","author":[{"given":"Julia","family":"D\u2019Agata Mount","sequence":"first","affiliation":[{"name":"The George Washington University School of Medicine and Health Sciences  Washington DC USA"},{"name":"Critical Care Medicine Department, Clinical Center National Institutes of Health  Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Sun","sequence":"additional","affiliation":[{"name":"Critical Care Medicine Department, Clinical Center National Institutes of Health  Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Davis","sequence":"additional","affiliation":[{"name":"Division of Clinical Care and Research Institute of Human Virology, University of Maryland School of Medicine  Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Cover","sequence":"additional","affiliation":[{"name":"Division of Clinical Care and Research Institute of Human Virology, University of Maryland School of Medicine  Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Sun","sequence":"additional","affiliation":[{"name":"Haverford College  Haverford PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Gannon","sequence":"additional","affiliation":[{"name":"Critical Care Medicine Department, Clinical Center National Institutes of Health  Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Derenoncourt","sequence":"additional","affiliation":[{"name":"Critical Care Medicine Department, Clinical Center National Institutes of Health  Bethesda Maryland USA"},{"name":"Division of Clinical Care and Research Institute of Human Virology, University of Maryland School of Medicine  Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Garrett","sequence":"additional","affiliation":[{"name":"Critical Care Medicine Department, Clinical Center National Institutes of Health  Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahwa","family":"Eyasu","sequence":"additional","affiliation":[{"name":"Division of Clinical Care and Research Institute of Human Virology, University of Maryland School of Medicine  Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emade","family":"Ebah","sequence":"additional","affiliation":[{"name":"Division of Clinical Care and Research Institute of Human Virology, University of Maryland School of Medicine  Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phyllis","family":"Bijole","sequence":"additional","affiliation":[{"name":"HIPS, Org  Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Greenblatt","sequence":"additional","affiliation":[{"name":"Division of Addiction Research and Treatment, Department of Psychiatry University of Maryland School of Medicine  Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kattakuzhy","sequence":"additional","affiliation":[{"name":"Division of Clinical Care and Research Institute of Human Virology, University of Maryland School of Medicine  Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7234-4871","authenticated-orcid":false,"given":"Elana","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"Division of Clinical Care and Research Institute of Human Virology, University of Maryland School of Medicine  Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"Centers for Disease Control and Prevention.Death rate maps and graphs|drug overdose.|CDC Injury Center.2022. Available at:https:\/\/www.cdc.gov\/drugoverdose\/deaths\/index.html(accessed 23 Decmber 2022)."},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.12333"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.181506"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1550"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.27488"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2013.10.004"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-017-1415-y"},{"key":"e_1_2_10_9_1","unstructured":"Indivior Pharmaceuticals. Suboxone (buprenorphine\u2010naloxone) package insert. Revised 2021. US Food and Drug Administration website. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/020733s028lbl.pdf(accessed 23 December 2022)."},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-005-0023-6"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/ael051"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300251"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2014.07.035"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/00952990.2011.643988"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.1572"},{"key":"e_1_2_10_16_1","unstructured":"Medicaid Coverage of Medication\u2010Assisted Treatment for Alcohol and Opioid Use Disorders and of Medication for the Reversal of Opioid Overdose. 119."},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.12201"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa105"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39335.541782.AD"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1086\/340827"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/14659891.2019.1572805"},{"key":"e_1_2_10_22_1","unstructured":"National Institutes of Health (NIH).Reduced drug use is a meaningful treatment outcome for people with stimulant use disorders.2024. Available at:https:\/\/www.nih.gov\/news-events\/news-releases\/reduced-drug-use-meaningful-treatment-outcome-people-stimulant-use-disorders(accessed 13 February 2024)."},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/10550490701860971"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.07.013"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2022.107589"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001189"},{"key":"e_1_2_10_27_1","unstructured":"MAT_buprenorphine_products.pdf. Available at:https:\/\/www.hca.wa.gov\/assets\/billers-and-providers\/MAT_buprenorphine_products.pdf(accessed 15 January 2024)."},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2010.03.014"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2013.08.008"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102722"}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.16600","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T03:37:52Z","timestamp":1729049872000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/add.16600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1111\/add.16600"],"URL":"https:\/\/doi.org\/10.1111\/add.16600","archive":["Portico"],"relation":{},"ISSN":["0965-2140","1360-0443"],"issn-type":[{"value":"0965-2140","type":"print"},{"value":"1360-0443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,8]]},"assertion":[{"value":"2023-09-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}